Works matching IS 01676997 AND DT 2020 AND VI 38 AND IP 6

Results: 31

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1836, doi. 10.1007/s10637-020-00968-5

By:

Kondo, Shunsuke;
Tajimi, Masaomi;
Funai, Tomohiko;
Inoue, Koichi;
Asou, Hiroya;
Ranka, Vinay Kumar;
Wacheck, Volker;
Doi, Toshihiko

Publication type:

Article

Correction to: The old CEACAMs find their new role in tumor immunotherapy.

Published in:

2020

By:

Han, Zi-Wen;
Lyv, Zhi-Wu;
Cui, Bin;
Wang, Ying-Ying;
Cheng, Jun-Ting;
Zhang, Ying;
Cai, Wen-Qi;
Zhou, Yang;
Ma, Zhao-Wu;
Wang, Xian-Wang;
Peng, Xiao-Chun;
Cui, Shu-Zhong;
Xiang, Ying;
Yang, Mo;
Xin, Hong-Wu

Publication type:

Correction Notice

Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.

Published in:

2020

By:

Kondo, Shunsuke;
Tajimi, Masaomi;
Funai, Tomohiko;
Inoue, Koichi;
Asou, Hiroya;
Ranka, Vinay Kumar;
Wacheck, Volker;
Doi, Toshihiko

Publication type:

Correction Notice

Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1743, doi. 10.1007/s10637-020-00979-2

By:

Song, Tao;
Zhang, Mingyu;
Wu, Jun;
Chen, Fenghua;
Wang, Ying;
Ma, Yujie;
Dai, Zhijie

Publication type:

Article

Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1872, doi. 10.1007/s10637-020-00965-8

By:

Gorodnova, Tatyana V.;
Sokolenko, Anna P.;
Kondratiev, Sergey V.;
Kotiv, Khristina B.;
Belyaev, Alexey M.;
Berlev, Igor V.;
Imyanitov, Evgeny N.

Publication type:

Article

Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1915, doi. 10.1007/s10637-020-00963-w

By:

Nasu, Shingo;
Suzuki, Hidekazu;
Shiroyama, Takayuki;
Tanaka, Ayako;
Samejima, Yumiko;
Kanai, Tomohiro;
Noda, Yoshimi;
Morishita, Naoko;
Okamoto, Norio;
Hirashima, Tomonori

Publication type:

Article

The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1730, doi. 10.1007/s10637-020-00961-y

By:

Liu, Guihong;
Lu, Yachun;
Li, Liantao;
Jiang, Tao;
Chu, Sufang;
Hou, Pingfu;
Bai, Jin;
Chen, Ming

Publication type:

Article

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1815, doi. 10.1007/s10637-020-00960-z

By:

Lemech, Charlotte;
Woodward, Natasha;
Chan, Nancy;
Mortimer, Joanne;
Naumovski, Louie;
Nuthalapati, Silpa;
Tong, Bo;
Jiang, Fang;
Ansell, Peter;
Ratajczak, Christine K.;
Sachdev, Jasgit

Publication type:

Article

First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1826, doi. 10.1007/s10637-020-00959-6

By:

Wang, Meng-na;
Kuang, Yun;
Gong, Li-ying;
Hua, Ye;
Pei, Qi;
Guo, Cheng-xian;
Cao, Yu;
Huang, Jie;
Yang, Guo-ping

Publication type:

Article

Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1696, doi. 10.1007/s10637-020-00956-9

By:

Hong, Seung-Woo;
Shin, Jae-Sik;
Moon, Jai-Hee;
Jung, Soo-A;
Koh, Dong-In;
Ryu, Yeaseong;
Park, Yoon Sun;
Kim, Do Yeon;
Park, Sang-Soo;
Hong, Jun Ki;
Kim, Eun Ho;
Kim, Mi Jin;
Jeong, Hong-Rae;
Bae, In Hwan;
Ahn, Young-Gil;
Suh, Kwee Hyun;
Cho, Ig-Jun;
Kang, Jong-Soon;
Hong, Yong Sang;
Lee, Jung Shin

Publication type:

Article

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1774, doi. 10.1007/s10637-020-00928-z

By:

Delord, Jean-Pierre;
Argilés, Guillem;
Fayette, Jerôme;
Wirth, Lori;
Kasper, Stefan;
Siena, Salvatore;
Mesia, Ricard;
Berardi, Rossana;
Cervantes, Andrés;
Dekervel, Jeroen;
Zhao, Sylvia;
Sun, Yongjian;
Hao, Huai-Xiang;
Tiedt, Ralph;
Vicente, Sergio;
Myers, Andrea;
Siu, Lillian L.

Publication type:

Article

The old CEACAMs find their new role in tumor immunotherapy.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1888, doi. 10.1007/s10637-020-00955-w

By:

Han, Zi-Wen;
Lyv, Zhi-Wu;
Cui, Bin;
Wang, Ying-Ying;
Cheng, Jun-Ting;
Zhang, Ying;
Cai, Wen-Qi;
Zhou, Yang;
Ma, Zhao-Wu;
Wang, Xian-Wang;
Peng, Xiao-Chun;
Cui, Shu-Zhong;
Xiang, Ying;
Yang, Mo;
Xin, Hong-Wu

Publication type:

Article

Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1717, doi. 10.1007/s10637-020-00952-z

By:

Zhang, Ying;
Garofano, Francesca;
Wu, Xiaolong;
Schmid, Matthias;
Krawitz, Peter;
Essler, Markus;
Schmidt-Wolf, Ingo G. H.

Publication type:

Article

Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1707, doi. 10.1007/s10637-020-00951-0

By:

Chen, Hao;
Zhu, Xiaoling;
Sun, Rong;
Ma, Panpan;
Zhang, Erhao;
Wang, Zhou;
Fan, Yihui;
Zhou, Guoxiong;
Mao, Renfang

Publication type:

Article

The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1641, doi. 10.1007/s10637-020-00934-1

By:

Zheng, Yu;
Hou, Guangdong;
Zhang, Geng;
Lan, Ting;
Yuan, Jiarui;
Zhang, Lei;
Yan, Fei;
Wang, Fuli;
Meng, Ping;
Dun, Xinlong;
Li, Xi'an;
Chen, Guo;
Zhu, Zheng;
Wei, Di;
He, Wei;
Yuan, Jianlin

Publication type:

Article

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1664, doi. 10.1007/s10637-020-00931-4

By:

Opydo-Chanek, Małgorzata;
Cichoń, Iwona;
Rak, Agnieszka;
Kołaczkowska, Elżbieta;
Mazur, Lidia

Publication type:

Article

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1796, doi. 10.1007/s10637-020-00953-y

By:

Pierrillas, Philippe B.;
Henin, Emilie;
Ogier, Julien;
Amiel, Magali;
Kraus-Berthier, Laurence;
Chenel, Marylore;
Bouzom, François;
Tod, Michel

Publication type:

Article

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1784, doi. 10.1007/s10637-020-00950-1

By:

Reardon, David A.;
Desjardins, Annick;
Rixe, Olivier;
Cloughesy, Timothy;
Alekar, Shilpa;
Williams, Jason H.;
Li, Ray;
Taylor, Carrie Turich;
Lassman, Andrew B.

Publication type:

Article

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1807, doi. 10.1007/s10637-020-00945-y

By:

McGregor, Bradley A.;
Gordon, Michael;
Flippot, Ronan;
Agarwal, Neeraj;
George, Saby;
Quinn, David I.;
Rogalski, Mark;
Hawthorne, Thomas;
Keler, Tibor;
Choueiri, Toni K.

Publication type:

Article

Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1854, doi. 10.1007/s10637-020-00943-0

By:

Nakashima, Kazuhisa;
Ozawa, Yuichi;
Daga, Haruko;
Imai, Hisao;
Tamiya, Motohiro;
Tokito, Takaaki;
Kawamura, Takahisa;
Akamatsu, Hiroaki;
Tsuboguchi, Yuko;
Takahashi, Toshiaki;
Yamamoto, Nobuyuki;
Mori, Keita;
Murakami, Haruyasu

Publication type:

Article

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1906, doi. 10.1007/s10637-020-00948-9

By:

Igawa, Satoshi;
Ono, Taihei;
Kasajima, Masashi;
Kusuhara, Seiichiro;
Otani, Sakiko;
Fukui, Tomoya;
Yokoba, Masanori;
Kubota, Masaru;
Katagiri, Masato;
Mitsufuji, Hisashi;
Sasaki, Jiichiro;
Naoki, Katsuhiko

Publication type:

Article

Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1901, doi. 10.1007/s10637-020-00947-w

By:

Ogawa, Koichi;
Kaneda, Hiroyasu;
Kawamoto, Tamaki;
Tani, Yoko;
Izumi, Motohiro;
Matsumoto, Yoshiya;
Sawa, Kenji;
Suzumura, Tomohiro;
Watanabe, Tetsuya;
Mitsuoka, Shigeki;
Asai, Kazuhisa;
Kawaguchi, Tomoya

Publication type:

Article

ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1687, doi. 10.1007/s10637-020-00946-x

By:

Sakamoto, Sho;
Sato, Kazuhiro;
Takita, Yuri;
Izumiya, Yuka;
Kumagai, Naho;
Sudo, Kazuhisa;
Hasegawa, Yukiyasu;
Yokota, Hayato;
Akamine, Yumiko;
Okuda, Yuji;
Asano, Mariko;
Takeda, Masahide;
Sano, Masaaki;
Miura, Masatomo;
Nakayama, Katsutoshi

Publication type:

Article

Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1633, doi. 10.1007/s10637-020-00940-3

By:

Kim, Bum Jun;
Kim, Yoo Jin;
Sohn, Sung-Hwa;
Kim, Bohyun;
Sul, Hee Jung;
Kim, Hyeong Su;
Zang, Dae Young

Publication type:

Article

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1755, doi. 10.1007/s10637-020-00936-z

By:

Zhu, Mojun;
Molina, Julian R.;
Dy, Grace K.;
Croghan, Gary A.;
Qi, Yingwei;
Glockner, James;
Hanson, Lorelei J.;
Roos, Michelle M.;
Tan, Angelina D.;
Adjei, Alex A.

Publication type:

Article

CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1653, doi. 10.1007/s10637-020-00941-2

By:

da Silva, Elisa Feller Gonçalves;
Lima, Kelly Goulart;
Krause, Gabriele Catyana;
Haute, Gabriela Viegas;
Pedrazza, Leonardo;
Catarina, Anderson Velasque;
Gassen, Rodrigo Benedetti;
de Souza Basso, Bruno;
Dias, Henrique Bregolin;
Luft, Carolina;
Garcia, Maria Claudia Rosa;
Costa, Bruna Pasqualotto;
Antunes, Géssica Luana;
Basso, Luiz Augusto;
Donadio, Márcio Vinícius Fagundes;
Machado, Pablo;
de Oliveira, Jarbas Rodrigues

Publication type:

Article

Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1677, doi. 10.1007/s10637-020-00933-2

By:

Phanhthilath, Nikki;
Hakim, Sara;
Su, Catherine;
Liu, Andrea;
Subramonian, Divya;
Lesperance, Jacqueline;
Zage, Peter E.

Publication type:

Article

Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C<sub>max</sub> and improved tolerability, in patients with solid tumors.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1763, doi. 10.1007/s10637-020-00939-w

By:

Ajani, Jaffer A.;
Javle, Milind;
Eng, Cathy;
Fogelman, David;
Smith, Jackie;
Anderson, Barry;
Zhang, Chun;
Iizuka, Kenzo

Publication type:

Article

Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1879, doi. 10.1007/s10637-020-00938-x

By:

Cabarrou, Bastien;
Gomez-Roca, Carlos;
Viala, Marie;
Rabeau, Audrey;
Paulon, Rodolphe;
Loirat, Delphine;
Munsch, Nadia;
Delord, Jean-Pierre;
Filleron, Thomas

Publication type:

Article

A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1862, doi. 10.1007/s10637-020-00927-0

By:

Wang, Yuxiao;
Li, Xuemei;
Zhang, Liang;
Li, Mengxia;
Dai, Nan;
Luo, Hao;
Shan, Jinlu;
Yang, Xueqin;
Xu, Mingfang;
Feng, Yan;
Xu, Chengxiong;
Qian, Chengyuan;
Wang, Dong

Publication type:

Article

Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.

Published in:

Investigational New Drugs, 2020, v. 38, n. 6, p. 1847, doi. 10.1007/s10637-020-00925-2

By:

Li, Ling;
Kong, Fei;
Zhang, Lei;
Li, Xin;
Fu, Xiaorui;
Wang, Xinhua;
Wu, Jingjing;
Zhang, Fangwen;
Ren, Liangliang;
Zhang, Mingzhi

Publication type:

Article